NCT05644626View on ClinicalTrials.gov

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

August 31, 2025

Conditions

Solid Tumors

Interventions

DRUG

BGB-B167

Intravenous administration

DRUG

Tislelizumab

Intravenous administration

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BeiGene

INDUSTRY

NCT05644626 - Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants | Biotech Hunter | Biotech Hunter